Connect with us

News

Cloud-based Information Governance Industry by Marketing Channel (Direct Marketing, Indirect Marketing), Products Sales, Revenue, Size, Price and Gross Margin

gbafNews28

The research report on Global “Cloud-based Information Governance Market” report primarily focuses on the market trends, demand spectrum, and future prospects of this industry over the forecast period. Furthermore, the report provides a detailed statistical overview in terms of trends outlining the geographical opportunities and contributions by prominent industry share contenders. The report is a comprehensive collection of essential data with respect to the competitive spectrum of this industry where the Cloud-based Information Governance market has profitably established its presence.

Request a Sample Copy of the Reporthttps://www.industryresearch.co/enquiry/request-sample/14499061

About Cloud-based Information Governance Market:

  • Information governance is the application of technologies, policies, and processes to maximize the value of information from inception to final disposal. It helps organization manage information risks, reduce information costs, and maximize business benefits. Information governance includes traditional records management, information security and protection, electronic discovery, data storage and archiving, and risk management. The life cycle of information governance includes creation, protection, value creation, preservation, and final placement of the information.
  • With the proliferation of cloud market and social media governance, information management is crucial for all corporate organizations. Rise in need for advanced information management solutions, technological advancements, and rise in legal threats among enterprises drive the growth of the global cloud-based information governance market. However, low awareness among end users towards the benefits associated with information governance is expected to impede the market growth. Conversely, increase in demand for cloud-based solutions is expected to provide lucrative opportunities for the market during the forecast period.
  • In 2018, the global Cloud-based Information Governance market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

Top Key Manufacturers in Worldwide Cloud-based Information Governance Market Are:

  • EMC
  • HP Autonomy
  • IBM
  • Symantec
  • AccessData
  • Amazon
  • BIA
  • Catalyst
  • Cicayda
  • Daegis
  • Deloitte
  • Ernst and Young
  • FTI
  • Gimmal
  • Google
  • Guidance Software
  • Index Engines
  • Iron Mountain
  • Konica Minolta
  • Kroll Ontrak
  • Microsoft
  • Mimecast
  • Mitratech
  • Proofpoint
  • RenewData
  • RSD
  • TransPerfect

Cloud-based Information Governance Market Report Segment by Types:

  • Simple Storage And Retrieval
  • Basic Document Management
  • Complex Document Management
  • Functional Applications With Document Storage
  • Social Networking Applications With Document Storage

Cloud-based Information Governance Market Report Segmented by Application:

  • BFSI
  • Public
  • Retail
  • Manufacturing
  • IT And Telecom
  • Healthcare
  • Others

Inquire And Share Your Questions If Any Before The Purchase on This Report at:https://www.industryresearch.co/enquiry/pre-order-enquiry/14499061

Regions Covered in Cloud-based Information Governance Market Report:

  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East and Africa

Some of The Key Questions Answered in This Report:

  • Detailed Overview of Cloud-based Information Governance market will help deliver clients and businesses making strategies.
  • Influencing factors that thriving demand and latest trend running in the market.
  • What is the market concentration? Is it fragmented or highly concentrated?
  • What trends, challenges and barriers will impact the development and sizing of Global Cloud-based Information Governance market?
  • SWOT Analysis of each defined key players along with its profile and Porter’s five forces tool mechanism to compliment the same.
  • What growth momentum or acceleration market carries during the forecast period?
  • Which region may tap highest market share in coming era?
  • Which application/end-user category or Product Type may seek incremental growth prospects?
  • What focused approach and constraints are holding the Cloud-based Information Governance market?

Purchase This Report (Price 3900 USD for A Single-User License)https://www.industryresearch.co/purchase/14499061

Detailed TOC of Cloud-based Information Governance Market Report 2019-2025:

1 Study Coverage

1.1 Cloud-based Information Governance Product

1.2 Key Market Segments in This Study

1.3 Key Manufacturers Covered

1.4 Market by Type

1.5 Market by Application

2 Executive Summary

2.1 Global Cloud-based Information Governance Market Size

2.2 Cloud-based Information Governance Growth Rate (CAGR) 2019-2025

2.3 Analysis of Competitive Landscape

2.4 Key Trends for Cloud-based Information Governance Markets and Products

3 Market Size by Manufacturers

3.1 Cloud-based Information Governance Production by Manufacturers

3.2 Cloud-based Information Governance Revenue by Manufacturers

3.3 Cloud-based Information Governance Price by Manufacturers

3.4 Mergers and Acquisitions, Expansion Plans

4 Cloud-based Information Governance Production by Regions

4.1 North America

4.2 Europe

4.3 China

4.4 Southeast Asia

4.5 India

5 Breakdown Data by Type and Applications

5.1 Global Cloud-based Information Governance Market Size by Type

5.2 Global Market Size by Applications

6 Market Size by Type

6.1 Global Cloud-based Information Governance Production by Type

6.2 Global Cloud-based Information Governance Revenue by Type

6.3 Cloud-based Information Governance Price by Type

7 Market Size by Application

7.1 Overview

7.2 Global Cloud-based Information Governance Breakdown Data by Application

Continued……

Contact Us:
Name: Ajay More
Phone: US +1424 253 0807/ UK +44 203 239 8187
Email ID: [email protected]

News

Cut the Queues and Stop the Data Fakers: Anyline Launches Contactless Smartphone ID Scanning for Hospitality Industry

gbafNews28

‹Hotels, pubs, and restaurants across Australia are pulling back punters, but losing time to typing. Track and trace regulations require establishments to register information on each guest, causing delays for many patrons, while others are deliberately falsifying their data.

Tackling these issues, Austrian technology firm Anyline has launched software to scan Australian driving licenses and passports on any smartphone. This technology give hospitality personnel a quick and contactless way to gather the data needed from each guest on entry. In contrast to QR code systems, guests do not need to type in their information themselves, meaning incorrect data cannot be entered.

The hospitality industry is caught between a rock and a hard place: fighting every day to protect jobs and welcome back guests while doing all in their power to ensure safety, said Anyline CEO Lukas Kinigadner. But when the staff has a quick and contactless way to register each guest with their own phone, it’s possible to cut the queues, stop anyone entering fake data and ensure the best records are kept for contact tracing.

The company, founded in 2013, is noted for offering its technology for free to emergency and humanitarian services as the COVID-19 pandemic took hold, and is currently used by the United Nations World Food Programme (WFP) for aid distribution. Their technology has also been integrated into the LEAD Horizon COVID-19 home test kits which are sold widely in Austria, delivering results within 24 hours.

(ENDS)

About Anyline

Anyline has established itself as a market leader in mobile text recognition. Using the newest and most innovative artificial intelligence approaches, Anyline enables any mobile device to process written characters in real-time, even when offline. Its not only more accurate than manual data entry but also works 20 times faster.

Anyline is the trusted choice for ID scanning for leading companies and national governments and is used by over 100,000 police officers around the world in their daily work. In Austria, it has also been integrated into a ˜Digital Office app which can be used by every Austrian resident to complete municipal tasks such as abode registrations.

The same technology will also soon be integrated to scan new ˜E-Vaccination Passports, which will vastly improve the process of recording vaccinations. With the most recent Anyline release, verification for IDs in the EU, North America, and Australia are already in active use with extended coverage planned steadily over the coming months.

With over 300 active business clients producing more than 1 million mobile scans every day, it is clear that the future of data collection is automation and we are proud to be leading the global change.

Anyline GmbH

Michael Wilkinson

Head of Public Relations

+43 6704046048

[email protected]

Continue Reading

News

Frontier Communications Prices $1.150 Billion First Lien Secured Notes Offering

gbafNews28

Frontier Communications Corporation (OTC: FTRCQ) (Frontier Communications) announced today that it has priced its previously announced offering of $1.150 billion aggregate principal amount of First Lien Secured Notes due 2027 (the First Lien Secured Notes) in a private transaction. The First Lien Secured Notes will bear interest at 5.875% per year and will be sold at a price equal to 100% of the principal thereof. The settlement of the First Lien Secured Notes is expected to occur on or about October 8, 2020, subject to customary closing conditions.

Frontier Communications intends to use the proceeds from the offering, together with proceeds of a $500 million new first lien term loan facility (the New Term Loan Facility) and cash on hand to (i) repay in full the $1.650 billion principal balance of the existing prepetition 8.000% First Lien Secured Notes due 2027 and (ii) pay related interest, fees and expenses incurred in connection therewith. The offering of First Lien Secured Notes is subject to market and other conditions. The New Term Loan Facility will be entered into at a price equal to 98.50% of its face value and will bear interest at a rate equal to, at the option of Frontier Communications, either LIBOR plus 4.75% or Base Rate plus 3.75%, with a 1.00% LIBOR floor.

As previously disclosed, on April 14, 2020, Frontier Communications and certain of its subsidiaries commenced voluntary cases (the Chapter 11 Cases) under Chapter 11 of the United States Bankruptcy Code (Bankruptcy Code) in the United States Bankruptcy Court for the Southern District of New York (the Bankruptcy Court). On August 21, 2020, the Bankruptcy Court confirmed Frontier Communications plan of reorganization (the Plan) for the resolution of the outstanding claims against and interests in Frontier Communications pursuant to section 1121(a) of the Bankruptcy Code. The implementation of the Plan is dependent upon a number of conditions typical in similar reorganizations, including the obtainment of regulatory approval. On September 17, 2020, the Bankruptcy Court issued a final order authorizing Frontier Communications to obtain debtor-in-possession financing, including approval for this offering.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sales of securities mentioned in this press release in any jurisdiction in which such offer, solicitation or sale would be unlawful.

All offers of the First Lien Secured Notes were made only by means of a private offering memorandum to persons reasonably believed to be qualified institutional buyers under Rule 144A under the Securities Act of 1933, as amended (the Securities Act) and to non-U.S. persons outside of the United States under Regulation S under the Securities Act. The First Lien Secured Notes have not been registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Frontier Communications

Frontier Communications Corporation (OTC: FTRCQ) offers a variety of services to residential and business customers over its fiber-optic and copper networks in 25 states, including video, high-speed internet, advanced voice, and Frontier Secure digital protection solutions. Frontier Business„¢ offers communications solutions to small, medium, and enterprise businesses.

Forward-Looking Statements

This press release contains forward-looking statements related to future events. Forward-looking statements address Frontier Communications expected future business, financial performance, and financial condition, and contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “may,” “will,” “would,” or “target.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. For Frontier Communications, particular uncertainties that could cause actual results to be materially different than those expressed in such forward-looking statements include: our ability to continue as a going concern; our ability to successfully consummate the restructuring of our existing debt, existing equity interests, and certain other obligations (the Restructuring), and emerge from the Chapter 11 Cases in Bankruptcy Court, including by satisfying both the conditions in the Plan and the conditions and milestones in the restructuring support agreement; our ability to improve our liquidity and long-term capital structure and to address our debt service obligations through the Restructuring and the potential adverse effects of the Chapter 11 Cases on our liquidity and results of operations; our ability to maintain relationships with suppliers, customers, employees and other third parties as a result of the Restructuring and the Chapter 11 Cases; the effects of the Restructuring and the Chapter 11 Cases on us and the interests of various constituents; risks and uncertainties associated with the Restructuring, including our ability to satisfy the conditions precedent for effectiveness of and successfully consummate the Restructuring in accordance with the Plan under the Chapter 11 Cases; our ability to comply with the restrictions expected to be imposed by covenants in debtor-in-possession and exit financing; the length of time that we will operate under Chapter 11 protection and the continued availability of operating capital during the pendency of the Chapter 11 Cases; risks associated with third party motions in the Chapter 11 Cases, which may interfere with the Companys ability to consummate the Restructuring; increased administrative and legal costs related to the Chapter 11 process; declines in revenue from our voice services, switched and nonswitched access and video and data services that we cannot stabilize or offset with increases in revenue from other products and services; declines in Adjusted EBITDA relative to historical levels that we are unable to offset through potential EBITDA enhancements; our ability to successfully implement strategic initiatives, including opportunities to enhance revenue and realize productivity improvements; our ability to effectively manage our operations, operating expenses, capital expenditures, debt service requirement and cash paid for income taxes and liquidity; competition from cable, wireless and wireline carriers, satellite, and over the top companies, and the risk that we will not respond on a timely or profitable basis; our ability to successfully adjust to changes in the communications industry, including the effects of technological changes and competition on our capital expenditures, products and service offerings; risks related to disruption in our networks, infrastructure and information technology that result in customer loss and/or incurrence of additional expenses; the impact of potential information technology or data security breaches or other cyber-attacks or other disruptions; our ability to retain or attract new customers and to maintain relationships with customers, employees or suppliers; our ability to secure, continue to use or renew intellectual property and other licenses used in our business; changes to our board of directors and management team upon our emergence from bankruptcy or in anticipation of emergence, and our ability to hire or retain key personnel; our ability to dispose of certain assets or asset groups on terms that are attractive to us, or at all; the effects of changes in the availability of federal and state universal service funding or other subsidies to us and our competitors and our ability to obtain future federal and state universal service funding and other subsidies; our ability to meet our Connect America Fund (CAF) Phase II obligations and the risk of penalties or obligations to return certain CAF Phase II funds; our ability to defend against litigation and potentially unfavorable results from current pending and future litigation; our ability to comply with applicable federal and state consumer protection requirements; the effects of state regulatory requirements that could limit our ability to transfer cash among our subsidiaries or dividend funds up to the parent company; the effects of governmental legislation and regulation on our business, including costs, disruptions, possible limitations on operating flexibility and changes to the competitive landscape resulting from such legislation or regulation; the impact of regulatory, investigative and legal proceedings and legal compliance risks; government infrastructure projects (such as highway construction) that impact our capital expenditures; continued reductions in switched access revenues as a result of regulation, competition or technology substitutions; our ability to effectively manage service quality in the states in which we operate and meet mandated service quality metrics; the effects of changes in income tax rates, tax laws, regulations or rulings, or federal or state tax assessments, including the risk that such changes may benefit our competitors more than us, as well as potential future decreases in the value of our deferred tax assets; the effects of changes in accounting policies or practices, including potential future impairment charges with respect to our intangible assets or additional losses on assets held for sale; the effects of increased medical expenses and pension and postemployment expenses; our ability to successfully renegotiate union contracts; changes in pension plan assumptions, interest rates, discount rates, regulatory rules and/or the value of our pension plan assets, which could require us to make increased contributions to the pension plan in 2020 and beyond; adverse changes in economic, political and market conditions in the areas that we serve, the U.S. and globally, including but not limited to, changes resulting from epidemics, pandemics and outbreaks of contagious diseases, including the coronavirus global pandemic, or other adverse public health developments; and potential adverse impacts of the COVID-19 pandemic on our business and operations, including potential disruptions to the work of our employees arising from health and safety measures such as social distancing and working remotely, our ability to effectively manage increased demand on our network, our ability to maintain relationships with our current or prospective customers and vendors as well as their abilities to perform under current or proposed arrangements with us, and stress on our supply chain. Forward-looking statements are also subject to the risk factors and cautionary language described from time to time in the reports the Company files with the U.S. Securities and Exchange Commission, including those in the Companys most recent Annual Report on Form 10-K and any updates thereto in the Companys Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These risks and uncertainties may cause actual future results to be materially different than those expressed in such forward-looking statements. Frontier Communications has no obligation to update or revise these forward-looking statements and does not undertake to do so.

Investors:

Jacob Noyes

203-614-5074

Sr. Analyst, Treasury and Investor Relations

[email protected]

Media:

Javier Mendoza

562-305-2345

Vice President, Corporate Communications and External Affairs

[email protected]

Meaghan Repko / Jed Repko

Joele Frank Wilkinson Brimmer Katcher

212-355-4449

Continue Reading

News

Mundipharma Welcomes the New 2020 Clinical Practice Guideline from KDIGO recommending SGLT2is alongside metformin as first-line anti-hyperglycaemic therapy in type 2 diabetes patients with chronic kidney disease

gbafNews28

As the European distributor of Invokana (canagliflozin) and Vokanamet (canagliflozin and metformin), Mundipharma welcomes the publication of the first KDIGO (Kidney Disease: Improving Global Outcomes) 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD). The new guideline recommends the use of sodium-glucose co-transporter-2 inhibitor (SGLT2i) class, which includes canagliflozin, as a first-line treatment option alongside metformin for the management of hyperglycaemia in patients with type 2 diabetes mellitus (T2DM), CKD and eGFR ‰¥30 ml/min/1.73 m2.1

This new guideline includes data from CV outcomes trials (CVOTs) for SGLT2is which give evidence of significant cardioprotective and possible kidney-protective effects across the class. This includes the positive CV outcomes data for canagliflozin,2 empagliflozin and dapagliflozin, and CKD outcomes from the canagliflozin CREDENCE clinical trial.3 The guideline also highlights that whilst kidney events were secondary outcomes in most of the CVOTs, CREDENCE was the first randomised controlled trial specifically powered for primary renal outcomes among patients exclusively with albuminuric CKD.3

The CREDENCE trial is the first dedicated renal outcomes study in patients with DKD and T2DM. The study enrolled 4401 subjects with an eGFR of 30 to <90ml/min/1.73m2 and albuminuria (urinary albumin: creatinine ratio >300 to 5000 mg/g). Importantly, all patients were treated on a background of standard of care for DKD, including a maximum tolerated dose of an ACE inhibitor or ARB. The results showed that canagliflozin demonstrated a 30% reduction, compared to placebo, in the risk of the primary composite endpoint, comprising end-stage renal disease (ESRD), doubling of serum creatinine and renal or cardiovascular (CV) death, with event rates of 43.2 vs 61.2 per 1000 patient years, respectively (Hazard Ratio [HR]: 0.70; 95% Confidence Interval [CI]: 0.57 to 0.84; p<0.0001).5

Canagliflozin received approval from the European Commission (EC) in July this year, to extend its treatment of T2DM indication in Europe to treat diabetic kidney disease (DKD) in T2DM patients.6 It is currently the only SGLT2i labelled to treat DKD in TD2M patients.

The KDIGO recommendations are based on evidence from recent clinical trials. These trials include CREDENCE, which demonstrated that canaglifozin reduced the risk of deteriorating kidney function and associated cardiovascular complications in patients with both type 2 diabetes and chronic kidney disease. CREDENCE is one reason why SGLT2 inhibitors have been given a prime position in diabetes management in the guideline, said Professor David Wheeler, Professor of Kidney Medicine at University College London and Honorary Consultant Nephrologist at the Royal Free NHS Foundation Trust, London, UK.

An estimated 59 million adults in Europe currently live with diabetes and around 90% of these have T2DM. This figure is set to rise to 68 million by 2045.7 If left untreated, people with T2DM are at greater risk of developing serious health complications, such as CKD, heart failure (HF), and CV disease, which is the most common cause of death amongst them.8 It is estimated that approximately 40% of people with T2DM will go on to develop CKD,4 so effective therapies need to be sought rapidly to halt the progression of the disease.1

People with type 2 diabetes and chronic kidney disease are at greater risk of cardiovascular disease and progression to end-stage kidney disease, so it is of paramount importance that physicians have clear guidelines which recommend appropriate therapies to help prevent these risks, said Dr Vinicius Gomes de Lima, European Medical Affairs Lead, Mundipharma.

The KDIGO guideline can be viewed at: https://kdigo.org/wp-content/uploads/2018/03/KDIGO-Diabetes-in-CKD-GL.pdf.

-END-

Notes to the editors:

About the KDIGO Guideline1 The first KDIGO (Kidney Disease: Improving Global Outcomes) Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease was published in https://kdigo.org/wp-content/uploads/2018/03/KDIGO-Diabetes-in-CKD-GL.pdf.

About Invokana (canagliflozin) Canagliflozin is an oral, once-daily medication that belongs to a class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors. SGLT2 inhibitors work by inhibiting SGLT2 co-transporter, which promotes the excretion of glucose via the urine, and thus helps lowering blood glucose levels in adults with T2DM.5

Canagliflozin was approved in the European Union by the European Commission in November 2013. It is indicated for the treatment of adults with insufficiently controlled T2DM as an adjunct to diet and exercise, as monotherapy when metformin is considered inappropriate due to intolerance or contra-indications and in addition to other medicinal products for the treatment of diabetes.5

The recommended initiation dose of canagliflozin is 100 mg once daily in adults with an eGFR of ‰¥ 60 mL/min/1.73 m2 and can be increased to 300 mg once daily if tighter glycaemic control is needed. For patients with an eGFR of 45 to <60 mL/min/1.73 m2 the initiation dose is limited to 100mg once daily, if further glycaemic control is needed the addition of other anti-hyperglycaemic agents should be considered. In patients with an eGFR of 30 to < 45 mL/min/1.73 m2 with a urinary albumin/creatinine ratio ˃ 300 mg/g, the initiation dose is limited to 100 mg once daily, if further glycaemic control is needed the addition of other anti-hyperglycaemic agents should be considered. Canagliflozin should not be initiated if eGFR is below 30 mL/min/1.73 m2, but for patients already taking canagliflozin it should be continued at 100 mg until dialysis or renal transplantation is required.5

Approval was based on a comprehensive global Phase III clinical trial programme.

About the CANVAS Programme2 The CANVAS Programme (N=10,142) comprised the two large canagliflozin cardiovascular outcome trials, CANVAS and CANVAS-R, and included a pre-specified integrated analysis of these two studies to evaluate the potential for CV protection of canagliflozin in patients with T2DM who had either a prior history of CV disease or at least two CV risk factors. The integrated analysis also evaluated the effects of canagliflozin on renal and safety outcomes.

Canagliflozin met the primary outcome by significantly reducing the rates of the composite of major adverse CV events (MACE) comprised of CV mortality, non-fatal myocardial infarction (MI), or non-fatal stroke (26.9 vs. 31.5/1000 patient-years, hazard ratio (HR) 0.86; 95% confidence interval (CI 0.75-0.97; P<0.0001 for non-inferiority; P=0.0158 for superiority) compared with placebo plus standard of care, respectively. All 3 components of MACE composite (CV death, non-fatal MI, and non-fatal stroke) exhibited point estimates of effect suggesting benefit with canagliflozin.

Adverse events reported in the CANVAS Programme were generally consistent with the known safety profile of canagliflozin. Whilst an increase in lower limb amputation and bone fractures were observed in the CANVAS Programme, this signal was not observed in further long term clinical trial data involving high risk patients.3

About the CREDENCE Clinical Trial3 The CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) study was the first dedicated and fully recruited renal outcome trial evaluating renal and cardiovascular outcomes in people with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) with a sodium glucose co-transporter 2 (SGLT2) inhibitor. It was a phase III randomised, double-blind, event-driven, placebo-controlled, parallel-group, two-arm multicentre study of the effects of canagliflozin on renal and cardiovascular outcomes in subjects with T2DM and CKD. In particular, it compared the efficacy and safety of canagliflozin versus placebo in preventing clinically important kidney and cardiovascular outcomes in patients with T2DM and CKD when used in addition to standard of care, including a maximum tolerated daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB).

About the Mundipharma network Mundipharma is a global (ex-US) network of privately-owned independent associated companies with a presence across Africa, Asia Pacific, Europe, Canada, Latin America and the Middle East.

We are dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as Anti-Infectives, Biosimilars, CNS, Diabetes, Oncology & supportive care, Ophthalmology, Pain Management, Respiratory and Consumer Healthcare.

For further information by geographic region please go to www.mundipharma.com (Europe); www.purdue.ca (Canada) and www.mundipharma.com.sg (other ex-US markets).

Invokana is a registered trademark of Johnson & Johnson. The Marketing Authorisation Holder is Janssen-Cilag International NV.

References:


1 KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International. Oct 2020; 98(4S): S1“S115. Available at https://kdigo.org/wp-content/uploads/2018/03/KDIGO-Diabetes-in-CKD-GL.pdf. Last accessed September 2020.

2 Neal B et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. The New England Journal of Medicine (2017);377:644-657.

3 Perkovic, V. et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephrology. The New England Journal of Medicine. 2019; 380(24): 2295-2306.

4Alicic R, Rooney M, Tuttle K. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017; 12(12):2032-45.

5 Invokana SMPC. Updated July 2020 https://www.medicines.org.uk/emc/product/8855 Last accessed July 2020

6 European Commission. 26th June 2020 Decision C(2013)8171(final) for Invokana “ canagliflozin. Available at https://ec.europa.eu/health/documents/community-register/html/h884.htm. Last accessed July 2020.

7 IDF Diabetes Atlas Ninth Edition 2019. Available at: https://www.diabetesatlas.org/en/resources/ Last accessed July 2020

8 Einarson T, Acs A, Ludwig C. et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018 Jun 8;17(1):83.

Job code: MINT/MINVK-20034 Date of preparation: October 2020

For further information please contact:

Cendrine Banerjee-Quetel

Asset Communications Associate, Mundipharma International Ltd

Email: [email protected]

Tel: +44 (0) 1223 393 009

Abbie Bell

Account Director, Havas SO

E-mail: [email protected]

Tel: +44 7375 660 515

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News2 hours ago

Cut the Queues and Stop the Data Fakers: Anyline Launches Contactless Smartphone ID Scanning for Hospitality Industry

‹Hotels, pubs, and restaurants across Australia are pulling back punters, but losing time to typing. Track and trace regulations require...

gbafNews28 gbafNews28
News2 hours ago

Frontier Communications Prices $1.150 Billion First Lien Secured Notes Offering

Frontier Communications Corporation (OTC: FTRCQ) (Frontier Communications) announced today that it has priced its previously announced offering of $1.150 billion...

gbafNews28 gbafNews28
News2 hours ago

Mundipharma Welcomes the New 2020 Clinical Practice Guideline from KDIGO recommending SGLT2is alongside metformin as first-line anti-hyperglycaemic therapy in type 2 diabetes patients with chronic kidney disease

As the European distributor of Invokana (canagliflozin) and Vokanamet (canagliflozin and metformin), Mundipharma welcomes the publication of the first KDIGO...

gbafNews28 gbafNews28
News2 hours ago

Automotive Powder Metallurgy Components Market – Actionable Research on COVID-19 | Energy Saving and Cost Advantages to Boost Market Growth | Technavio

The global automotive powder metallurgy components market size is poised to grow by USD 1.06 billion during 2020-2024, progressing at...

gbafNews28 gbafNews28
News2 hours ago

Schnitzer Announces Fourth Quarter Fiscal 2020 Earnings Date and Conference Call Webcast Details

Schnitzer Steel Industries, Inc. (NASDAQ: SCHN) today announced that the Company will report financial results for its fourth quarter and...

gbafNews28 gbafNews28
News2 hours ago

BMW of North America Reports Q3 2020 Sales Results.

BMW of North America announced today Q3 2020 sales results for the BMW and MINI brands in the U.S. For...

gbafNews28 gbafNews28
News2 hours ago

McLarens Acquires Leading New Zealand Claims Services Company CNZ Group

McLarens, a leading, global independent insurance services provider, is pleased to announce the strategic acquisition of CNZ Group Holdings Limited...

gbafNews28 gbafNews28
News3 hours ago

BBX Capital, Inc. Announces Approval for Trading of its Class A Common Stock on the OTCQX

BBX Capital, Inc. (OTCQX: BBXIA) (PINK: BBXIB) (the Company), which was spun-off by Bluegreen Vacations Holding Corporation (the former BBX...

gbafNews28 gbafNews28
News3 hours ago

Lathrop GPM Taps Jasmine Trillos-Decarie for Innovative Chief Client Officer Role

Lathrop GPM LLP announces that Jasmine Trillos-Decarie joins the firm as its first Chief Client Officer after an exhaustive search...

gbafNews28 gbafNews28
News3 hours ago

20 Tech Startups Taking Their Next Steps in Platform Calgary’s Junction Program

Platform Calgary is pleased to announce the 20 companies participating in the Junction program. Junction is a nine-week full-time residency...